Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial

Authors

Külli Kingo (ORCID: https://orcid.org/0000-0001-6301-9612)
Stefan Beissert
Asunción Vicente Villa
Nina Magnolo (ORCID: https://orcid.org/0000-0001-6802-0153)
Amita Bansal (ORCID: https://orcid.org/0000-0001-8716-9922)
Jirina Bartonová
Heng Fan (ORCID: https://orcid.org/0000-0003-4519-1130)
Ruvie Martin
Rosalía Ballona
Svetlana Lazareva
Shoba Ravichandran
P. Papanastasiou
Catherine O’Doherty

Institutions

Novartis (Switzerland) (CH)
Hospital Sant Joan de Déu Barcelona (ES)
Tartu University Hospital (EE)
Novartis (China) (CN)
University Hospital Münster (DE)
Novartis (United States) (US)
University Hospital Hradec Králové (CZ)
National Institute of Quality (PE)
Skin Research Center (FR)
Novartis (Ireland) (IE)
University of Tartu (EE)
Technische Universität Dresden (DE)

Publication Details

Journal: Pediatric Drugs
Published: 2025-08-28
DOI: https://doi.org/10.1007/s40272-025-00715-4
Citations: 1
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 0.80

Funders

Novartis Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial

Külli Kingo, Stefan Beissert, Asunción Vicente Villa, Nina Magnolo et al.

Aug 28, 2025

1 citations

Pediatric Drugs

Psoriasis: Treatment and Pathogenesis

0.80

article

Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial

Külli Kingo, Stefan Beissert, Asunción Vicente Villa, Nina Magnolo, Amita Bansal, Jirina Bartonová, Heng Fan, Ruvie Martin, Rosalía Ballona, Svetlana Lazareva, Shoba Ravichandran, P. Papanastasiou, Catherine O’Doherty

August 28, 2025article en

1 citations

Abstract

No abstract available for this paper.

Pediatric DrugsVol. 27(6)

Novartis (Switzerland) (CH), Hospital Sant Joan de Déu Barcelona (ES), Tartu University Hospital (EE), Novartis (China) (CN), University Hospital Münster (DE), Novartis (United States) (US), University Hospital Hradec Králové (CZ), National Institute of Quality (PE), Skin Research Center (FR), Novartis (Ireland) (IE), University of Tartu (EE), Technische Universität Dresden (DE)

Novartis Pharma

Good health and well-being

Openalex Percentile: Top 24%

Psoriasis: Treatment and Pathogenesis

0.80

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial — Külli Kingo, Stefan Beissert, et al. · Pediatric Drugs (2025) | TGRS Research Map | TGRS